EZH2 Expression Correlates With T-Cell Infiltration in Oral Leukoplakia and Predicts Cancer Transformation

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
INT INST ANTICANCER RESEARCH
Autores
GANESH, Divya
DAFAR, Amal
NIKLASSON, Julia
SANDBERG, Ingrid
SAPKOTA, Dipak
OHMAN, Jenny
GIGLIO, Daniel
HASSEUS, Bengt
Citação
ANTICANCER RESEARCH, v.43, n.4, p.1533-1542, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background/Aim: The EZH2 complex is involved in cellular proliferation and modulates the immune response in cancer. Less is known about the importance of EZH2 in precancerous lesions such as oral leukoplakia (OL). The aim of the study was to explore the association between EZH2 expression, immune activation, and cancer transformation in OL. Patients and Methods: Analyses were retrospectively performed on nine OL cases that had undergone transformation to oral squamous cell carcinoma (OSCC; OL-ca) and nine that had not undergone transformation (OL-non). EZH2-expressing cells, CD3+ and CD8+ T cells, and CD1a+ Langerhans cells were visualized with immunohistofluorescence and counted. Results: A moderate positive correlation between CD3-and EZH2-expressing and CD8-and EZH2-expressing cells in the epithelium was found (r=0.57, p=0.01; r=0.59, p=0.01). The number of EZH2-expressing cells in the epithelium of OL-ca was significantly higher compared to OL-non (p=0.0002). Cancer - free survival rates differed significantly between patients with EZH2high compared to EZH2low expression (p=0.001). EZH2high expression in OL epithelium was associated with a 13-fold higher risk for developing OSCC (HR=12.8). Conclusion: EZH2 expression in oral epithelium predicts OSCC transformation of OL and correlates with the level of T-cell infiltration.
Palavras-chave
Oral potentially malignant disorder, oral cancer, polycomb group proteins, immune cells, biomarker
URI
https://observatorio.fm.usp.br/handle/OPI/59260
Referências
  1. Balgkouranidou I, 2016, CLIN CHEM LAB MED, V54, P1385, DOI 10.1515/cclm-2015-0776
  2. Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5
  3. Cao W, 2011, CANCER PREV RES, V4, P1816, DOI 10.1158/1940-6207.CAPR-11-0130
  4. Chen GB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00549
  5. Chow A.Y., 2010, NATURE ED, V3, P7
  6. Ciferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005
  7. Dong HP, 2019, CANCER RES, V79, P5587, DOI 10.1158/0008-5472.CAN-19-0428
  8. Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
  9. Gannot G, 2002, BRIT J CANCER, V86, P1444, DOI 10.1038/sj.bjc.6600282
  10. Gao HX, 2016, INTERACT CARDIOV TH, V23, P681, DOI 10.1093/icvts/ivw198
  11. Gibbings D, 2009, J LEUKOCYTE BIOL, V86, P251, DOI 10.1189/jlb.0109040
  12. Gunawan M, NAT IMMUNOL, V16, P5
  13. Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMRA021902
  14. He S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02187-8
  15. Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
  16. Hu YL, 2009, CLIN CHEM LAB MED, V47, P923, DOI 10.1515/CCLM.2009.228
  17. Huang YJ, 2023, IMMUNOLOGY, V168, P30, DOI 10.1111/imm.13588
  18. Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107, 10.3322/caac.21492]
  19. Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307
  20. Kang YN, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.658241
  21. Lande R, 2010, ANN NY ACAD SCI, V1183, P89, DOI 10.1111/j.1749-6632.2009.05152.x
  22. Lodish H, 2000, MOL CELL BIOL
  23. Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
  24. Markopoulou S, 2012, CLIN CHEM LAB MED, V50, P1723, DOI 10.1515/cclm-2012-0124
  25. Massano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038
  26. Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653
  27. Öhman J, 2012, SCAND J IMMUNOL, V76, P39, DOI 10.1111/j.1365-3083.2012.02701.x
  28. Öhman J, 2015, ANTICANCER RES, V35, P311
  29. Parreno V, 2022, CELL RES, V32, P231, DOI 10.1038/s41422-021-00606-6
  30. Pasini D, 2016, CURR OPIN GENET DEV, V36, P50, DOI 10.1016/j.gde.2016.03.013
  31. Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004
  32. Pinto AC, 2020, OR SURG OR MED OR PA, V129, P600, DOI 10.1016/j.oooo.2020.02.017
  33. Russ BE, 2014, IMMUNITY, V41, P853, DOI 10.1016/j.immuni.2014.11.001
  34. Shao FF, 2021, J LEUKOCYTE BIOL, V110, P77, DOI 10.1002/JLB.1RU0520-311R
  35. Sperandio M, 2023, J ORAL PATHOL MED, V52, P418, DOI 10.1111/jop.13365
  36. Toraño EG, 2012, CLIN CHEM LAB MED, V50, P1733, DOI 10.1515/cclm-2011-0902
  37. Tumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012
  38. Vrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm-2013-0770
  39. Warnakulasuriya S, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104550
  40. Xu SB, 2023, ORAL DIS, V29, P3268, DOI 10.1111/odi.14332
  41. Zhang SZ, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19020875
  42. Zhang XL, 2018, J EXP MED, V215, P1365, DOI 10.1084/jem.20171417

Coleções
Artigos e Materiais de Revistas Científicas - LIM/52